Abstract:OBJECTIVES: Cell-free DNA based non-invasive prenatal testing (NIPT) has been shown with closeto-diagnosis sensitivity and specificity in detecting fetal T21, T18, and T13. Future development of this technology focuses on detection of other chromosomal aneuploidies, and more importantly chromosome copy number variants (CNVs) and single-gene mutations. Validation studies were carried out to demonstrate the feasibility of detecting CNVs and single-gene disease by exploiting the cell-free DNA testing strategy and existing NIPT platforms. METHOD: For testing CNVs, 35 plasma samples with known fetal CNVs (>10 Mb in size) were recruited, together with 1077 plasma samples with normal fetal karyotypes as the control. The samples were blindly tested using the routine NIPT testing pipelines adopted at the clinical laboratories of BGI, and analyzed with the proprietary FCAPS protocol. Results were compared to the karyotyping results to calculate the sensitivity and specificity of the NIPT test. For testing single-gene disease, we developed a unique haplotype-assisted approach which was validated in a Maple Syrup Urine Disease (MSUD) case. In a trio family (father, mother in early pregnancy, and proband), targeted sequencing (180X) of the known genes causing MSUD was used to identify the disease causative mutations in the proband child and parents. At 13 gestational weeks, maternal plasma DNA and genomic DNA of the trio family were tested with a customized array at the sequencing depth of 40X and 20X respectively to retrieve the SNPs information for the purpose of parental haplotypes deduction. Linkage analysis and Hidden Markov Model were then used to construct the fetal genotype and haplotype flanking the MSUD mutation region. RESULTS: For CNV detection, with on average 4–5 M reads per sample and the existing NIPT platforms, we were able to use the FCAPS analytic protocol to identify 32 positive samples in total of 35, and generated 6 false positive cases, leading to overall sensitivity and specificity of 91.4% and 99.4% respectively. False positive rate and false negative rate of the test were 0.56% and 0.28% respectively. We also showed that with an increased sequencing depth, the detection power of the test can be further improved. In the MUSD case, deep targeted sequencing in the trio family identified that the proband child carries a missense mutation and a large deletion on BCKDHA gene, which were inherited from the mother and father respectively. With the SNP markers of the proband and parents, parental haplotype of chromosome 19 in 6148 loci were recovered. After fetal haplotype construction, the same alleles as that of the proband in the causative gene BCKDHA were inherited to the fetus, indicating that the fetus is a MSUD patient. This result was later confirmed by invasive diagnosis, and led to a well-informed decision after post-test counselling. CONCLUSIONS: We demonstrate the successful application of NIPT in detection of CNVs larger than 10 Mb without changing much to the current pipelines of aneuploidy detection. It has the potential to be integrated into the current NIPT test and offer extra benefits to the clinical service. The haplotype-assisted approach we developed requires minimum genetic information to accurately predict fetal condition. It has the clinical potential for noninvasive prenatal diagnosis of single gene disease for family with a proband child and seeks a second healthy child.

High-resolution DNA Screening Based on Novel Magnetic Separation Technology

A nano-magnetic size selective cfDNA extraction platform for liquid biopsy with enhanced precision

Noninvasive detection of chromosomal CNV and single gene disease by massively parallel sequencing of cfDNA

A method for noninvasive detection of fetal large deletions/duplications by low coverage massively parallel sequencing.

High-resolution DNA size enrichment using a magnetic nano-platform and application in non-invasive prenatal testing

A nanoflow cytometric strategy for sensitive ctDNA detection via magnetic separation and DNA self-assembly

Single Molecule Sequencing of Cell-free DNA from Maternal Plasma for Noninvasive Trisomy Detection

Increased Detection of Circulating Tumor DNA by Short Fragment Enrichment

The Fragmentation Patterns of Maternal Plasma Cell-Free DNA and Its Applications in Non-Invasive Prenatal Testing.

基于新型磁分离技术的高分辨率 DNA 片段筛选技术

Genetic deconvolution of fetal and maternal cell-free DNA in maternal plasma enables next-generation non-invasive prenatal screening

Highly Sensitive and Rapid Isolation of Fetal Nucleated Red Blood Cells with Microbead-Based Selective Sedimentation for Non-Invasive Prenatal Diagnostics

Detection of cell-free fetal DNA in maternal plasma using two types of compound markers.

Size-selective separation and overall-amplification of cell-free fetal DNA fragments using PCR-based enrichment

Non-Invasive Prenatal Diagnosis: A Comparison of Cell Free Fetal DNA (cffdna) Based Screening and Fetal Nucleated Red Blood Cell (fnrbc) Initiated Testing

Ultrafast and Highly Specific Detection of One-Base Mutated Cell-Free DNA at a Very Low Abundance

Separation of ctDNA by superparamagnetic bead particles in microfluidic platform for early cancer detection

Based on Magnetic Beads to Develop the Kit for Extraction of High-Quality Cell-Free DNA from Blood of Breast Cancer Patients

Aptamer-Mediated Enrichment of Rare Circulating Fetal Nucleated Red Blood Cells for Noninvasive Prenatal Diagnosis

Noninvasive Detection of Fetal Subchromosomal Abnormalities by Semiconductor Sequencing of Maternal Plasma DNA

Detection of Circulating Fetal DNA in Maternal Plasma for Non-Invasive Prenatal Diagnosis